Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive

Summary

This study is an open-label, single arm, phase II trial the efficacy and safety of pembrolizumab + CapeOx (HER2 negative ARM) or pembrolizumab + Trastuzumab + Capecitabine/Cisplatin (HER2 positive ARM) as first line therapy in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Timeline

Start

2020-09-29

Primary completion

2024-02-06

Completion

2025-03

Publications

• Lim SH, Kuwata T, An M, Hong JY, Kim ST, Matsubara Y, Shitara K, Lee J. Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. J Immunother Cancer. 2025 Sep 29;13(9):e012683. doi: 10.1136/jitc-2025-012683.

Drugs

Indications